100 Participants Needed

Research Network for Hereditary Spastic Paraplegia

(SP-CERN Trial)

Recruiting at 10 trial locations
DE
NB
Overseen ByNicole Battaglia, BS.
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: Boston Children's Hospital
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial focuses on hereditary spastic paraplegia (HSP), a condition that causes muscle stiffness and weakness, with the aim of better understanding and treating it. Researchers seek to study the progression of HSP, identify useful markers for tracking the disease, and find effective targets for new treatments. The trial seeks participants with specific types of HSP, known as SPG4 and SPG5A, confirmed by clinical and genetic tests. Participants will aid scientists in learning more about these conditions and testing potential new treatments. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to the development of a potentially groundbreaking treatment.

Why are researchers excited about this trial?

Spastic paraplegia treatments are usually centered around physical therapy and medications like muscle relaxants to manage symptoms. However, researchers are excited about this trial because it aims to establish a Centers of Excellence Research Network. This network is unique as it allows for comprehensive collaboration among top researchers and clinicians, potentially leading to faster discoveries and more effective treatments. By creating a hub of shared knowledge and resources, the trial seeks to accelerate the development of innovative therapies and improve patient outcomes more efficiently than traditional approaches.

Are You a Good Fit for This Trial?

Inclusion Criteria

I have been diagnosed with SPG4 or SPG5A hereditary spastic paraplegia.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Enrollment

Enrollment of 100 individuals with genetically-confirmed hereditary spastic paraplegia type 4 (SPG4) or hereditary spastic paraplegia type 5A (SPG5A) in the shared clinical database

4-8 weeks

Biobanking

Biobanking of blood samples from 100 individuals with SPG4 or SPG5A in a shared biobank

Ongoing

Follow-up

Participants are monitored for safety and effectiveness after enrollment and biobanking

6 months

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

Boston Children's Hospital

Lead Sponsor

Trials
801
Recruited
5,584,000+

University of Washington

Collaborator

Trials
1,858
Recruited
2,023,000+

University of Iowa

Collaborator

Trials
486
Recruited
934,000+

University of Michigan

Collaborator

Trials
1,891
Recruited
6,458,000+

Columbia University

Collaborator

Trials
1,529
Recruited
2,832,000+

University of Miami

Collaborator

Trials
976
Recruited
423,000+

University of Texas Southwestern Medical Center

Collaborator

Trials
1,102
Recruited
1,077,000+

Children's Hospital Medical Center, Cincinnati

Collaborator

Trials
844
Recruited
6,566,000+

Baylor College of Medicine

Collaborator

Trials
1,044
Recruited
6,031,000+

Massachusetts General Hospital

Collaborator

Trials
3,066
Recruited
13,430,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity